Stay updated on Efficacy of EID Natalizumab in RRMS Clinical Trial
Sign up to get notified when there's something new on the Efficacy of EID Natalizumab in RRMS Clinical Trial page.

Latest updates to the Efficacy of EID Natalizumab in RRMS Clinical Trial page
- Check9 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.0%
- Check16 days agoNo Change Detected
- Check23 days agoChange DetectedThe page has undergone significant changes, including the removal of detailed study objectives and criteria related to a clinical trial for natalizumab in treating relapsing-remitting multiple sclerosis, while adding new identifiers and a revision number.SummaryDifference16%
- Check30 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.0%
- Check37 days agoChange DetectedThe web page has been updated from version 2.14.2 to version 2.14.3.SummaryDifference0.0%
- Check66 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference0.7%
- Check88 days agoChange DetectedThe page now includes a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with a contact email for assistance.SummaryDifference0.7%
Stay in the know with updates to Efficacy of EID Natalizumab in RRMS Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Efficacy of EID Natalizumab in RRMS Clinical Trial page.